{{Rsnum
|rsid=2018643
|Gene=SLC2A9
|Chromosome=4
|position=9945497
|Orientation=minus
|GMAF=0.4027
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=SLC2A9
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 35.4 | 44.2 | 20.4
| HCB | 80.9 | 19.1 | 0.0
| JPT | 85.8 | 14.2 | 0.0
| YRI | 6.1 | 44.9 | 49.0
| ASW | 8.8 | 56.1 | 35.1
| CHB | 80.9 | 19.1 | 0.0
| CHD | 73.4 | 22.9 | 3.7
| GIH | 60.4 | 34.7 | 5.0
| LWK | 13.6 | 37.3 | 49.1
| MEX | 31.0 | 50.0 | 19.0
| MKK | 14.7 | 47.4 | 37.8
| TSI | 35.3 | 47.1 | 17.6
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2018643
|Name_s=
|Gene_s=SLC2A9
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00004. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109470
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2018643
|overall_frequency_n=57
|overall_frequency_d=128
|overall_frequency=0.445312
|n_genomes=38
|n_genomes_annotated=0
|n_haplomes=54
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}